boom $ qut, page-18

Thanks for the replies, COLIN and TDA - you're both gentlemen. From my observation there's a high degree of intelligence among TIS holders on this thread, and I enjoy swinging in here regularly to keep up with the discussion and some quality debates.

Imo, there's a healthier balance here in comparison to many other stock threads, although I suspect as Tissue Therapies begins to attract more investor interest in the near term, along with an anticipated ascending sp, there will always be that inevitable trade-off with an increase to low content posts.

On that note I want to extend another quick apology to you and your peers here, Colin, for the little bit of arrogance shown by me towards the end of my last post. Your courteous response only accentuated that, so I'm sorry.

In regards to posting information related to potential competition, whilst some holders may find value in that, I'm not sure if it would be considered by other holders as appropriate when coming from someone with no skin in the game. There will always be competition, and it would be futile for anyone to ignore that fact, however from where TIS and Vitrogro stand at this present time, there are some considerable advantages over most of the existing marketed competition.

For starters, most of the marketed competing technology to Vitrogro lacks the solid scientific evidence, and of the few, like Vitrogro, which are backed with positive efficacy data, the results in comparison have shown to be inferior, especially where consistency is concerned.

Secondly, where the shear size and generic competition prowess of a giant player like Teva may appear as a significant threat to a small company like Tissue Therapies, it's important to understand that the equation is not about TIS Vs Teva, where market share is concerned, but rather, Quintiles Vs Teva - And in this equation I believe TIS holders can be comforted by two important facts:
1. Quintiles is a seasoned veteran with an unbeaten record for both new product launches and sales of wound care products, whilst Teva can only boast of being the world's largest manufacturer of generic drugs, and are very new players in the wound care market.
2. Quintiles would have a significantly larger number of PhD's in its ground sales force teams than Teva, and I'd imagine in specialised sales target area's for wound care management, which requires dealing with fellow qualified medical practitioners, the PhD carries significant weight.

Hi TDA,

Prof Harding is arguably the world's foremost expert in wound care. Imo, he is the single best endorsement any prospective TIS investor like myself could wish for, and I wholeheartedly agree, you are extremely fortunate to have him in your company's corner. If you weren't already aware, Prof Harding also heads the Scientific Advisory Board for Dr Mercer's former employer, Smith & Nephew, and don't get me started on my CE Marking delay conspiracy theory, but I can guarantee you that whoever is charged with granting vitrogro's CE approval would undoubtedly have the upmost respect for Prof Harding's work, and Prof Harding would have a powerful influence over the regulatory decisions panel.

When one uses the term, "he wrote the book" I can promise you, in Prof Harding's case, it may be used in the literal sense when refering to both regulatory and classification guidance for ECM in acute and chronic wounds across all FDA, EMA and EU jurisdictions.

I can't remember the title I have the document filed under at this time but I promise to locate it for you to substantiate above comments, and post before noon today.

Thanks for your piece in regards to the Venowave technology to which i referenced yesterday. What I find interesting with the article in your link is that the content appears quite contradictory to that provided in yesterday's article.

Does the company wish to raise $1 million dollars or $10 billion dollars to further develop its wound care technology? I would imagine if the MD of that company is really serious about attracting even $5 billion dollars to develop his wound care technology, he'll probably be required to prove the technology can also cure cancer ;)

I stumbled on this following paper describing a similar wave stimulation technology as featured by the Canadian company - only this published work comes from your Prof Upton's research lab at the QUT. Prof Upton is not cited as an author on the publication, however her off-sider, Dr Edwards is: - A home-based progressive resistance exercise programme for patients with venous leg ulcers: a feasibility study